Cetlalimumab
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Cetlalimumab?
| |
| Therapeutic monoclonal antibody | |
| Source | Human |
| Target | ? |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
|
WikiDoc Resources for Cetlalimumab | |
|
Articles | |
|---|---|
|
Most recent articles on Cetlalimumab Most cited articles on Cetlalimumab | |
|
Media | |
|
Powerpoint slides on Cetlalimumab | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Cetlalimumab at Clinical Trials.gov Clinical Trials on Cetlalimumab at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Cetlalimumab
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Cetlalimumab Discussion groups on Cetlalimumab Patient Handouts on Cetlalimumab Directions to Hospitals Treating Cetlalimumab Risk calculators and risk factors for Cetlalimumab
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Cetlalimumab | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Cetlalimumab is a human monoclonal antibody which is used to treat cancer.
Human monoclonal antibodies ("-u-") | |
|---|---|
| "-limu-" (immune system) | immunosuppression: Adalimumab, Atorolimumab, Gantenerumab, Golimumab, Lerdelimumab, Metelimumab, Morolimumab, Ziralimumab
immune activation: Ipilimumab, Tremelimumab other: Bertilimumab |
| "-kinu-" (interleukin as target) | Canakinumab |
| "-tumu-" (cancer immunotherapy) | Adecatumumab, Anetumumab, Belimumab, Duntumumab, Iratumumab, Lexatumumab, Lucatumumab, Mapatumumab, Ofatumumab, Panitumumab, Pritumumab, Votumumab, Zalutumumab, Zanolimumab |
| "-osu-" (bone) | Denosumab |
| "-mulu-" (musculoskeletal) | Durimulumab, Durmulumab, Stamulumab |
| "-fungu-" (fungal) | Efungumab |
| "-viru-" (viral) | Exbivirumab, Libivirumab, Regavirumab, Sevirumab, Tuvirumab |
| "-bacu-" (bacterial) | Nebacumab, Raxibacumab |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
